| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
Endocrine Care |
Göteborg Pediatric Growth Research Center, Institute for the Health of Women and Children, Göteborg University (C.A.-L., M.E., K.A.W., E.N.), S-416 85 Göteborg; and Department of Pediatrics, Lund University (M.E.), 221 85 Lund, Sweden
Address all correspondence and requests for reprints to: Dr. Ensio Norjavaara, Queen Silvia Childrens Hospital, Göteborg University, Institute for the Health of Women and Children, Göteborg Pediatric Growth Research Center, S-416 85 Göteborg, Sweden. E-mail: ensio.norjavaara{at}astrazeneca.com
Abstract
The objective of pubertal induction in children with hypogonadism is to mimic spontaneous puberty in terms of physical and psychological development. In a clinical observation study, we induced puberty in 15 girls with hyper- or hypogonadotropic hypogonadism using low doses of transdermal estradiol patches attached only during the night and compared the estradiol concentrations obtained with those in healthy girls. Pubertal induction was started between the ages of 12.3 and 18.1 yr. A transdermal matrix patch of 17ß-estradiol (25 µg/24 h; Evorel, Janssen Pharmaceuticals-Cilag) was cut into pieces corresponding to 3.1, 4.2, or 6.2 µg/24 h initially and attached to the buttock. After 414 months, the dose was increased gradually. Serum 17ß-estradiol concentrations were measured every 2 h by RIA (detection limit, 6.0 pmol/L; 1.6 pg/mL).
The results show that it is possible to mimic the spontaneous levels as well as the diurnal pattern of serum 17ß-estradiol in early puberty, by cutting a transdermal 17ß-estradiol matrix patch and attaching a part of it, corresponding to 0.080.12 µg estradiol/kg BW, to the buttock nocturnally. In most of the girls, breast development occurred within 36 months of the start of treatment.
This article has been cited by other articles:
![]() |
C. Ankarberg-Lindgren and E. Norjavaara A purification step prior to commercial sensitive immunoassay is necessary to achieve clinical usefulness when quantifying serum 17 -estradiol in prepubertal children Eur. J. Endocrinol., January 1, 2008; 158(1): 117 - 124. [Abstract] [Full Text] [PDF] |
||||
![]() |
C. A. Bondy and for The Turner Syndrome Consensus Study Group Care of Girls and Women with Turner Syndrome: A Guideline of the Turner Syndrome Study Group J. Clin. Endocrinol. Metab., January 1, 2007; 92(1): 10 - 25. [Abstract] [Full Text] [PDF] |
||||
![]() |
R. L. Rosenfield, N. Devine, J. J. Hunold, N. Mauras, T. Moshang Jr., and A. W. Root Salutary Effects of Combining Early Very Low-Dose Systemic Estradiol with Growth Hormone Therapy in Girls with Turner Syndrome J. Clin. Endocrinol. Metab., December 1, 2005; 90(12): 6424 - 6430. [Abstract] [Full Text] [PDF] |
||||
![]() |
L. Soriano-Guillen, J. Coste, E. Ecosse, J. Leger, M. Tauber, S. Cabrol, M. Nicolino, R. Brauner, the StaTur Study Group, J.-L. Chaussain, et al. Adult Height and Pubertal Growth in Turner Syndrome after Treatment with Recombinant Growth Hormone J. Clin. Endocrinol. Metab., September 1, 2005; 90(9): 5197 - 5204. [Abstract] [Full Text] [PDF] |
||||
![]() |
S. Piippo, H. Lenko, P. Kainulainen, and I. Sipila Use of Percutaneous Estrogen Gel for Induction of Puberty in Girls with Turner Syndrome J. Clin. Endocrinol. Metab., July 1, 2004; 89(7): 3241 - 3247. [Abstract] [Full Text] [PDF] |
||||
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
| Endocrinology | Endocrine Reviews | J. Clin. End. & Metab. |
| Molecular Endocrinology | Recent Prog. Horm. Res. | All Endocrine Journals |